Silver Book Fact

Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections

Bressler N, Chang T, Fine J, Dolan C, et al. Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: Clinical trial results from MARINA and ANCHOR. Ophthalmol. 2010; 117(4). http://www.aaojournal.org/article/S0161-6420(09)00981-6/abstract

Reference

Title
Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: Clinical trial results from MARINA and ANCHOR
Publication
Ophthalmol
Publication Date
2010
Authors
Bressler N, Chang T, Fine J, Dolan C, et al.
Volume & Issue
Volume 117, Issue 4
Pages
747-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Screening and treatment for diabetic retinopathy in type 2 diabetes patients produces annual savings of 53,986 person-years of sight.  
  • Omega-3 polyunsaturated fatty acids have been found to protect against the development and progression of deterioration of the retina (retinopathy).  
  • The NEI-sponsored Ocular Hypertensive Treatment Study (OHTS) found that lowering intraocular pressure (IOP) by at least 20% produced a 50% protective benefit for individuals who had an elevated IOP but…  
  • In general, every 10 mmHg reduction in systolic blood pressure reduces the risk of diabetes complications by 12%.  
  • The ACCORD Eye Study found that combination lipid therapy with a fibrate and statin (compared with statin treatment alone) reduced progression of diabetic retinopathy in type 2 diabetics by around…